|
N = 347
|
MTX + prednisone (n = 85)
|
MTX + TNFi (n = 87)
|
MTX + CTLA-4Ig (n = 92)
|
MTX + IL-6Ri (n = 83)
|
P-value
|
|---|
|
Age, yearsa
|
62 (21–81)
|
58 (21–79)
|
58 (18–82)
|
53 (25–79)
|
0.29
|
|
Female sexb
|
58 (68%)
|
58 (67%)
|
62 (67%)
|
57 (69%)
|
0.99
|
|
BMI, kg/m2a
|
26 (18–43)
|
25 (19–37)
|
26 (18–38)
|
25 (20–43)
|
0.11
|
|
Current smokerb
|
12 (14%)
|
20 (23%)
|
18 (20%)
|
22 (27%)
|
0.22
|
|
Autoantibody status
| | | | |
0.55
|
|
RF-ACPA-b
|
11 (13%)
|
10 (11%)
|
11 (12%)
|
4 (5%)
|
–
|
|
RF+ACPA-b
|
5 (6%)
|
6 (7%)
|
5 (5%)
|
9 (11%)
|
–
|
|
RF-ACPA+b
|
11 (13%)
|
14 (16%)
|
12 (13%)
|
17 (20%)
|
–
|
|
RF+ACPA+b
|
57 (67%)
|
57 (66%)
|
64 (70%)
|
53 (64%)
|
–
|
|
Symptom duration, daysa,c
|
142 (25–813)
|
144 (41–702)
|
170 (37–731)
|
170 (37–691)
|
0.29
|
|
CDAIa
|
30.7 (7.8–62.8)
|
27.9 (8.1–68.7)
|
29.5 (14–68.4)
|
26.8 (8.4–55.2)
|
0.33
|
|
DAS28-CRPa
|
5.2 (2.6–7.7)
|
5.1 (2.2–8.3)
|
5.1 (3.3–7.6)
|
5.0 (2.7–7.3)
|
0.21
|
|
DAS28-ESRa
|
5.6 (3.6–8.2)
|
5.6 (2.7–8.7)
|
5.5 (3.7–8.1)
|
5.3 (2.6–7.9)
|
0.23
|
|
SJC-66a
|
13 (2–42)
|
12 (2–34)
|
11 (2–41)
|
10 (1–27)
|
0.10
|
|
TJC-68a
|
15 (2–47)
|
15 (1–47)
|
14 (0–62)
|
13 (0–47)
|
0.55
|
|
CRP, mg/ a
|
16 (0.5–216)
|
14 (0.5–180)
|
11 (0.3–146)
|
8.4 (0.3–82)
|
0.19
|
|
ESR, mm/ha
|
31 (4-108)
|
32 (4–98)
|
28 (4–115)
|
24 (2–84)
|
0.14
|
|
PGA, mma
|
58 (2–87)
|
57 (13–100)
|
61 (19–100)
|
59 (9–100)
|
0.18
|
- Missing data from one patient regarding BMI, RF, IFN day 1, IFN week 24, CDAI week 24, PGA week 24, and ESR week 24; from two patients regarding CRP day 1 and DAS28-ESR week 24; from three patients regarding CRP week 24; from four patients regarding CDAI day 1 and DAS28-CRP week 24; and from five patients regarding ESR day 1 and DAS28-ESR day 1
- MTX methotrexate, TNFi certolizumab-pegol, CTLA-4Ig abatacept, IL-6Ri tocilizumab, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, CDAI clinical disease activity index, DAS28 disease activity score 28 joints, SJC-66 swollen joint count, 66 joints, TJC-68 tender joint count, 68 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PGA patient global assessment
- aMedian (range), Kruskal-Wallis followed by Dunn’s multiple comparison test
- bn (%), Fisher’s exact test
- cRetrospective patient-reported joint pain before RA diagnosis
